Castle Biosciences CSTL Business Segments — NET REVENUES
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Castle Biosciences's business segments — net revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Castle Biosciences's business segments — NET REVENUES?
- Castle Biosciences (CSTL) reported business segments — NET REVENUES of $83.68M in Q1 2026.
- How has Castle Biosciences's business segments — NET REVENUES changed year-over-year?
- Castle Biosciences's business segments — NET REVENUES decreased by 4.9% year-over-year, from $87.99M to $83.68M.
- What is the long-term trend for Castle Biosciences's business segments — NET REVENUES?
- Over 3 years (2022 to 2025), Castle Biosciences's business segments — NET REVENUES has grown at a 35.9% compound annual growth rate (CAGR), from $137.04M to $344.23M.
- What does business segments — NET REVENUES mean?
- Represents the total gross revenue generated by the primary business segment after accounting for returns, allowances, and discounts. This metric serves as the top-line indicator of market demand and commercial success for the company's core product portfolio.